Eledon Pharmaceuticals
ELDN
31 hedge funds and large institutions have $15.9M invested in Eledon Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 3 closing their positions.
1.46% less ownership
Funds ownership: 48.95% → 47.49% (-1.5%)
3% less funds holding
Funds holding: 32 → 31 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
42% less capital invested
Capital invested by funds: $27.6M → $15.9M (-$11.7M)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$41.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$14.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.33K |
| 4 |
Morgan Stanley
New York
|
+$848 |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$58 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$477K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$389K |
| 3 |
EP
Eversept Partners
New York
|
-$168K |
| 4 |
V
Veritable
Wilmington,
Delaware
|
-$130K |
| 5 |
Two Sigma Advisers
New York
|
-$119K |
ELDN Hedge Fund Activity: Q2 2022 in Review
31 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2022, worth a combined $15.9M — down 42% from $27.6M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ELDN and 2 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $41.8K. The largest seller was Woodline Partners, cutting an estimated $477K.
- 31 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2022, down from 32 in Q1 2022.
- Funds reported $15.9M of Eledon Pharmaceuticals stock for Q2 2022, down 42% quarter-over-quarter.
- 2 funds opened new Eledon Pharmaceuticals positions in Q2 2022 and 3 closed out, a net change of -1 holder.
- The largest Eledon Pharmaceuticals buyer in Q2 2022 was Renaissance Technologies, an estimated $41.8K added.
- The largest Eledon Pharmaceuticals seller in Q2 2022 was Woodline Partners, an estimated $477K sold.
Based on aggregated 13F filings for Q2 2022.